Bacterial Conjunctivitis Drugs Market Is Driven by Rising Incidence of Ophthalmic Bacterial Infection
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can be predicted between small biotech research organizations and bigger pharmaceutical...
View full press release